ELEV | Elevation Oncology, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.6062 - 0.6640
52 Week Range	0.3630 - 5.83
Beta	1.35
Implied Volatility	574.90%
IV Rank	73.48%
Day's Volume	480,559
Average Volume	1,345,125
Shares Outstanding	59,106,800
Market Cap	36,055,148
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-06-25

Valuation
Profitability
Growth
Health
P/E Ratio	-0.90
Forward P/E Ratio	N/A
EPS	-0.68
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	29
Country	USA
Website	ELEV

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

ELEV's peers: ABSI, ADPT, AFMD, AKBA, ATOS, AVIR, BCTX, BNTX, BTAI, CNSP, CRBP, CYTO, DNA, DRUG, CWBR, OCEA, AVRO, ZURA, ENVB, HEPA, EXAI, AUGX, GERN, GNPX, IBRX, IMMP, IMMX, INO, INVA, LPTX, LXRX, MDXH, MNKD, MREO, MRNA, OCGN, ORMP, PDSB, PHIO, PLX, PYPD, PYXS, RIGL, SLS, SMMT, VKTX, VTVT, XERS, XFOR, BIOR, CDIO

*Chart delayed

Analyzing fundamentals for ELEV we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see ELEV Fundamentals page.

Watching at ELEV technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ELEV Technicals page.